Incyte Corp
Change company Symbol lookup
Select an option...
INCY Incyte Corp
QLGN Qualigen Therapeutics Inc
JOFF JOFF Fintech Acquisition Corp
IR Ingersoll Rand Inc
TGT Target Corp
CCLP CSI Compressco LP
BIOT Biotech Acquisition Co
XNXNX Nuveen New York Select Tax Free Income Portfolio
DHHC DiamondHead Holdings Corp
WFC Wells Fargo & Co
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Postmarket

Last Trade
Delayed
$84.03
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$84.03
Day's Change
1.49 (1.81%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
84.13
Day's Low
82.32
Volume
(Average)
Volume:
1,145,379

10-day average volume:
1,264,207
1,145,379
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.